Biomarin Pharmaceutical Inc.

Biomarin Pharmaceutical Inc. is a global biotechnology company specializing in therapies for rare, genetically defined diseases. The company focuses on developing and commercializing targeted treatments that address the underlying biology of serious inherited conditions, particularly enzyme deficiencies, skeletal disorders, and other complex genetic disorders. Its portfolio today includes enzyme replacement therapies, small-molecule and peptide drugs, and gene therapy for indications such as mucopolysaccharidoses, phenylketonuria, achondroplasia, severe hemophilia A, and certain neurodegenerative pediatric diseases. Biomarin Pharmaceutical Inc. generates most of its business from product sales to hospitals, specialty pharmacies, government agencies, and distributors, serving patients across North America, Europe, Latin America, the Middle East, and Asia-Pacific. Founded in 1997 and headquartered in San Rafael, California, the company plays a significant role in the rare disease segment of the biotechnology and pharmaceutical industries, providing highly specialized treatments where medical need is substantial and alternative options are limited.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Alexander Hardy

Employees

3,221

Headquarters

San Rafael, CA, United States

Website

www.biomarin.com